166 - A Phase 2b/3 Study to Evaluate the Efficacy and Safety of an Investigational Respiratory Syncytial Virus (RSV) Antibody, Clesrovimab, in Healthy Preterm and Full-Term Infants

Thursday, October 17, 2024

2:09 PM – 2:21 PM US PT

Location: 403 A

Co-Author(s)

HZ

Heather J. Zar, PhD

Red Cross Children's Hospital and SA-MRC Unit on Child & Adolescent Health, University of Cape Town, South Africa
Cape Town, Western Cape, South Africa
Eric Simoes, MD DCH

Professor of Pediatrics and Epidemiology
University of Colorado School of Medicine and Colorado School of Public Health
Denver, CO, United States

Co-Author(s)

SM

Sabhir Madhi, MD

Wits Vaccines & Infectious Diseases Analytics (VIDA) Research Unit
Johannesburg, Gauteng, South Africa

Co-Author(s)

OR

Octavio Ramilo, MD

Chair
St. Jude Children's Research Hospital
Memphis, TN, United States
SS

Shelly Senders, MD

Dr
Senders Pediatrics, Cleveland, Ohio, United States
Euclid, Ohio, United States
JS

Julie S. Shepard, MD, MPH

Ohio Pediatric Research Association
Dayton, Ohio, United States
KL

Kamolwish Laoprasopwattana, MD

Prince of Songkla University
Songkla, Pattani, Thailand
JP

Jorge Piedrahita, MD

Clinica de la Costa
Barranquilla, Atlantico, Colombia
JN

Jose M. Novoa Pizarro, MD

Hospital Padre Alberto Hurtado
Santiago, Region Metropolitana, Chile
SV

Sergio L. Vargas, MD

University Chile School of Medicine
Santiago, Region Metropolitana, Chile
MD

Marc Dionne, MD

CHU de Quebec-Universite Laval
Quebec City, Quebec, Canada
TJ

Teresa Jackowska, MD

Center of Postgraduate Medical Education & Bielanski Hospital
Warsaw, Mazowieckie, Poland
EL

Enmei Liu, MD

Children's Hospital of Chongqing Medical University
Chongqing, Chongqing, China
YI

Yasunori Ishihara, MD, PhD

Fukui Aiiku Hospital
Fukui, Gifu, Japan
KI

Kazushige Ikeda, MD

Saitama City Hospital
Saitama, Saitama, Japan
YZ

Ying Zhang, PhD

Merck & Co., Inc.
Kenilworth, New Jersey, United States
RR

Radha A. Railkar, PhD

Merck & Co., Inc.
Rahway, New Jersey, United States
JL

Jeannine Lutkiewicz, BS

Merck & Co., Inc.
Rahway, New Jersey, United States
AL

Andrew W. Lee, MD

Merck & Co., Inc., present affiliation Uniquity Bio, Malvern, PA, USA
Rahway, New Jersey, United States
Andrea Guerra, MD (he/him/his)

EMEA Regional Clinical Director
Merck Sharp & Dohme LLC - United Kingdom
London, England, United Kingdom

Presenting Author(s)

Anushua Sinha, MD, MPH

Director
Merck and Co Inc.
Rahway, NJ, United States

Disclosure(s):

Heather J. Zar, PhD: MSD, Pfizer, AstraZeneca, Moderna (DSMB): Advisor/Consultant, Grant/Research Support, Honoraria, MSD Principal Investigator for the study and on MSD Advisory Board

Eric Simoes, MD DCH: Pfizer, Sanofi, Merck, Icosavax, Enanta Cidara, Adiagio, Nuance, Shionogi, GIlead,: Advisor/Consultant, Grant/Research Support, Honoraria, MSD - PI for this study; DSMB Abbvie, Moderna, GSK

Sabhir Madhi, MD: Pfizer, GSK, Medimmune, Merck & Co., Inc., Rahway, NJ, USA: Grant/Research Support, Honoraria

Octavio Ramilo, MD: Pfizer, Sanofi, Gates Foundation, NIH, and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD): Advisor/Consultant, Grant/Research Support, Honoraria, SAC member for MSD

Shelly Senders, MD: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA: Principal Investigator

Julie S. Shepard, MD, MPH: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA: Principal Investigator

Kamolwish Laoprasopwattana, MD: Merck & Co., Inc., Rahway, NJ, USA: Grant/Research Support, MSD - PI for this study

Jorge Piedrahita, MD: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA: Principal Investigator

Jose M. Novoa Pizarro, MD: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD): Principal Investigator for the study for MSD

Sergio L. Vargas, MD: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA: Principal Investigator

Marc Dionne, MD: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA: Principal Investigator

Teresa Jackowska, MD: MSD Poland, Merck & Co., Inc, Rahway, NJ, USA: Advisor/Consultant, Grant/Research Support, Honoraria, MSD - PI for this study

Enmei Liu, MD: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA: Principal Investigator

Yasunori Ishihara, MD, PhD: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA: Principal Investigator

Kazushige Ikeda, MD: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA: Principal Investigator

Ying Zhang, PhD: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA: Employee, Stocks/Bonds (Public Company)

Radha A. Railkar, PhD: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, US (MSD): Employee, Stocks/Bonds (Public Company)

Jeannine Lutkiewicz, BS: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA: Employee, Stocks/Bonds (Public Company)

Andrew W. Lee, MD: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD): Employee at the time of study, Stocks/Bonds (Public Company)

Andrea Guerra, MD: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA: Employee, Stocks/Bonds (Public Company)

Anushua Sinha, MD, MPH: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD): Employee, Stocks/Bonds (Public Company)